Oncology Central

ASCO18: Early-stage breast cancer patients could be spared chemotherapy, TAILORx trial shows

Results from the Phase III TAILORx clinical trial have indicated that most women with hormone receptor-positive, HER2-negative, axillary node-negative early-stage breast cancer and a midrange score on a 21-tumor gene expression assay do not need chemotherapy after surgery.

Experts suggest that these findings, presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO; 1–5 June 2018, IL, USA), could have an immediate impact on clinical practice, sparing thousands of women the side effects of chemotherapy.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.